Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK961081 + propranolol
- Development stage
- Phase 1
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral, Inhalation
01
Overview
GSK961081 + propranolol is an investigational combination in which **GSK961081**, a bi-functional molecule (MABA) that combines muscarinic antagonist and β2 adrenergic agonist activities, is co-administered with **propranolol**, a non-selective beta-adrenergic antagonist. GSK961081 acts via bronchodilation through both muscarinic receptor blockade and β2 adrenoceptor agonism; propranolol blocks β-receptors (including β2), allowing study of the contribution of the muscarinic antagonist component alone. This combination has been studied in healthy volunteers to explore the pharmacology and contribution of each pharmacophore for respiratory indications such as COPD.
- Other names
- GSK961081 + propranolol
02
Targets
CHRM2 (M2)CHRM3 (M3)ADRB2 (β2)ADRB1 (β1)
Beyond the preview
Go deeper on GSK961081 + propranolol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK961081 + propranolol.